398 results on '"Sims, John R."'
Search Results
2. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
3. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
4. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
5. Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
6. Use of Donanemab in Early Symptomatic Alzheimer Disease—Reply
7. Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial
8. Amyloid Reduction: Donanemab Perspective
9. Using a newly validated algorithm to estimate prevalence and incidence of Alzheimer’s Disease and related dementias in Medicare claims
10. Natural cubic splines for the analysis of Alzheimer’s trials
11. Distinct associations between tau PET and cognitive impairment across brain regions and cognitive domains in Alzheimer’s disease
12. TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months
13. Characterize demographics, comorbidities and co‐medications in newly diagnosed United States (US) Alzheimer’s Disease patients using Medicare claims
14. Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials
15. Surgery for Locally Advanced Thyroid Cancer: Larynx, Tracheal Invasion, and Esophageal
16. Subtotal Resection of Jugular Paragangliomas
17. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
18. Trial of Solanezumab in Preclinical Alzheimer’s Disease
19. Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
20. Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients
21. APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials
22. Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease
23. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
24. Targeting amyloid β in Alzheimer's disease: Meta‐analysis of low‐dose solanezumab in Alzheimer's disease with mild dementia studies.
25. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease
26. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
27. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease
28. Disease progression model using the integrated Alzheimer's Disease Rating Scale
29. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
30. Subtotal Resection of Jugular Paragangliomas
31. Disease progression model using the integrated Alzheimer's Disease Rating Scale.
32. Clinical examination for prognostication in comatose cardiac arrest patients
33. Novel technique to prevent or correct open‐mouth deformity after bilateral mandibular resection: Use of tensor fascia lata slings
34. Integrated Alzheimer’s Disease Rating Scale (iADRS): Clinically Meaningful Change Estimates (P6-3.004)
35. TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (P18-3.005)
36. Multicolored stain-free histopathology with coherent Raman imaging
37. Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates
38. Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia
39. Novel use of tau imaging to enrich for pathological homogeneity within the PERISCOPE‐ALZ study of zagotenemab
40. TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment
41. Reproducibility of applying multiple statistical analyses to data from the TRAILBLAZER‐ALZ clinical trial of donanemab in early symptomatic Alzheimer's disease
42. Transoral robotic medial hypopharyngectomy: Surgical technique
43. Donanemab in Early Alzheimer’s Disease
44. Atypical metastasis of nasopharyngeal cancer: noncontiguous spread to the ipsilateral ear
45. Intra-arterial Air Thrombogenesis after Cerebral Air Embolism Complicating Lower Extremity Sclerotherapy
46. Dantrolene Mediates Vasorelaxation in Cerebral Vasoconstriction: A Case Series
47. Dantrolene: Mechanisms of Neuroprotection and Possible Clinical Applications in the Neurointensive Care Unit
48. Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
49. Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
50. Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.